Bolt Biotherapeutics (NASDAQ:BOLT) Given “Neutral” Rating at HC Wainwright

Bolt Biotherapeutics (NASDAQ:BOLT)‘s stock had its “neutral” rating restated by equities researchers at HC Wainwright in a report released on Tuesday,Benzinga reports.

Separately, Stifel Nicolaus lowered their price target on Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating on the stock in a research report on Tuesday. Five research analysts have rated the stock with a hold rating, According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $1.13.

Bolt Biotherapeutics Stock Performance

Shares of BOLT opened at $0.44 on Tuesday. The firm has a market capitalization of $16.84 million, a PE ratio of -0.26 and a beta of 0.94. The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.21. The firm has a 50-day moving average price of $0.47 and a 200 day moving average price of $0.56. Bolt Biotherapeutics has a 52-week low of $0.38 and a 52-week high of $1.56.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.38). The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.79 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. On average, sell-side analysts anticipate that Bolt Biotherapeutics will post -1.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bolt Biotherapeutics

Several large investors have recently made changes to their positions in BOLT. FMR LLC lifted its stake in Bolt Biotherapeutics by 33.2% during the third quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after purchasing an additional 28,773 shares during the last quarter. Millennium Management LLC acquired a new position in Bolt Biotherapeutics in the fourth quarter worth approximately $25,000. Squarepoint Ops LLC acquired a new stake in shares of Bolt Biotherapeutics during the 4th quarter valued at $26,000. Velan Capital Investment Management LP acquired a new stake in shares of Bolt Biotherapeutics during the 4th quarter valued at $27,000. Finally, Citadel Advisors LLC bought a new stake in shares of Bolt Biotherapeutics during the 4th quarter worth $42,000. Institutional investors own 86.70% of the company’s stock.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.